Aratana Therapeutics Inc (fka PETX)

[terry hallinan]

Aratana Therapeutics Reports First Quarter 2018 Financial Results

https://finance.yahoo.com/news/aratana-therapeutics-reports-first-quarter-200500768.html

On the side we have absolute proof that AI ["artificial intelligence"] is a farce. Computers can only pretend to think. The downbeat computer generated "analysis" isn't worth a used political slogan from the last campaign.

https://finance.yahoo.com/news/aratana-1q-earnings-snapshot-220620854.html

The shortfall in sales and earnings seems mostly the result of inventory adjustments with initial stocking of veterinary clinics.

This was a surprise to me regarding Galliprant that saved our middle-aged Border Collie/Labrador's life from the PETX PR:

GALLIPRANT, which is for the control of pain and inflammation associated with osteoarthritis in dogs, has quickly established itself as the second-leading therapeutic in a competitive category.

Our mail order supplier [the only way we can get the pills that require a veterinarian prescription but no local stores stock the drug] rated Galliprant even worse than a generic. A Minnesota cowboy offered to push my face in because I remarked on what Galliprant did for our dog while some fellow at a local university told the cowboy the regular drugs were best.

Apparently the word is getting around.

In February 2018, Aratana licensed exclusive, worldwide rights from AskAt Inc. to develop and commercialize AT-019, a potent and innovative EP4 receptor antagonist therapeutic candidate for pain, inflammation and other indications.

This is the secret sauce behind Galliprant. I expect PETX might discuss what looks to be completion of worldwide rights to the EP4 receptor antagonist that describes the MOA ["method of action"] of Galliprant that hopefully will soon be doing for humans what it does for dogs now.

Best, Terry